- In Vivo Originals
- Featured Topics
Growth
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

-
Analysis
Europe’s Big Pharma Players Begin Tricky 2022 In Style
By Kevin GroganBig pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.

-
Analysis
Providing A Better Last Mile Experience For Medtech And Patients
By Ashley YeoEvery part of health care today needs connectivity, says Cisco’s Troy Yoder. He explaines the unique role the company’s technology plays in ensuring patients get the best care the medtech industry can offer.

-
Analysis
2021 Global Biopharma R&D Productivity And Growth Ranking
By Markus Thunecke and Erika KuchenA turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

-
Interviews
A Guiding Hand For Biotech Start-Ups In Turbulent Times
By Kevin GroganRising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.

-
Analysis
A Tricky Outlook, But Medtech Has Opportunities To Grow
By Ashley YeoIn Vivo editorial advisory board member and ZS principal Brian Chapman identifies the agenda-topping themes for medtech bosses.

-
Analysis
5 Dealmaking Trends To Watch In 2022
By Andrew Odame-Kwakye2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

-
Analysis
2021 Deal-Making Snapshot
By Joseph HaasM&A deals valued at $10bn or more were scarce in 2021, as the industry focused on easier-to-integrate bolt-ons. Alliance activity increased, but the average value on licensing and partnership deals was lower than in 2020.

-
Analysis
2021 Venture Investment Was Bullish – Will 2022 Be The Same?
By Barnaby PickeringThe VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?

-
Analysis
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
By Joseph HaasTotals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

-
Analysis
Turning The Dial Up On Digital
By Jo ShorthouseThe maturation of digital offerings, coupled with commercially and clinically successful partnerships, has enabled huge investments in the digital health industry.

-
Analysis
Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?
By Lucie Ellis-TaittThe biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

-
Analysis
Infographic: Top 100 Pharma Companies
By Lucie Ellis-TaittThe Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.